A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (2) , 78-86
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Roche
- Bristol-Myers Squibb
- Celgene
- Amgen
- Novartis
- AstraZeneca
- Merck
This publication has 14 references indexed in Scilit:
- A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell LymphomaBlood, 2016
- A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic MalignanciesBlood, 2014
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignanciesOncoTargets and Therapy, 2014
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesHaematologica, 2014
- RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) CellsBlood, 2013
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002